Pune-based Gennova Biopharmaceuticals Ltd is creating an Omicron-specific Covid-19 vaccine that could be ready in a month or two, said an official. The manufacturer has nearly completed the phase 3 trials of its Covid-19 messenger or mRNA vaccine; it has started working on Omicron-specific vaccines using the same technology. The mRNA technology or messenger RNA affects the injection of a small part of the virus' genetic code (RNA) to produce the recipient's immune response. It holds instructions for the human cells to create proteins that resemble a component of the new coronavirus, trigger the immune system to act. The vaccine does not possess any actual virus.